{"id":"hydrocortisone-2-5","safety":{"commonSideEffects":[{"rate":null,"effect":"Skin atrophy"},{"rate":null,"effect":"Striae"},{"rate":null,"effect":"Telangiectasia"},{"rate":null,"effect":"Local irritation or burning"},{"rate":null,"effect":"Systemic absorption effects (with prolonged use)"}]},"_chembl":null,"_dailymed":{"setId":"5f055f94-b213-431b-897e-1c439660f158","title":"PROCTOZONE-HC (HYDROCORTISONE 2.5%) CREAM [PREFERRED PHARMACEUTICALS, INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Hydrocortisone (cortisol) is an endogenous glucocorticoid that exerts anti-inflammatory and immunosuppressive effects by translocating to the nucleus and modulating gene expression of inflammatory mediators. It reduces vasodilation, decreases vascular permeability, and inhibits leukocyte migration and activation. At 2.5% concentration in topical formulation, it provides localized anti-inflammatory effects for dermatological conditions.","oneSentence":"Hydrocortisone is a glucocorticoid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:41:37.246Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Inflammatory and pruritic dermatological conditions (topical)"},{"name":"Eczema, dermatitis, and other inflammatory skin disorders"}]},"trialDetails":[{"nctId":"NCT05423613","phase":"NA","title":"Microneedling for Burn Hypertrophic Scars","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre hospitalier de l'Université de Montréal (CHUM)","startDate":"2021-01-22","conditions":"Burn Scar","enrollment":36},{"nctId":"NCT06504160","phase":"PHASE1","title":"Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2)","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-04-10","conditions":"Atopic Dermatitis","enrollment":86},{"nctId":"NCT06979596","phase":"PHASE2","title":"A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-08-11","conditions":"Malignant Neoplasm","enrollment":250},{"nctId":"NCT05436535","phase":"PHASE4","title":"Longitudinal Endotyping Of Atopic Dermatitis Through Transcriptomic Skin Analysis","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2022-11-21","conditions":"Atopic Dermatitis","enrollment":433},{"nctId":"NCT06954441","phase":"PHASE3","title":"V-IMMUNE: A Novel Immunoglobulin Therapy for Immunodeficiency","status":"RECRUITING","sponsor":"On Pharma Importadora, Exportadora e Distribuidora de Medicamentos LTDA.","startDate":"2025-08-15","conditions":"Immunodeficiencies, Primary Immunodeficiencies (PID), Agammaglobulinemia","enrollment":50},{"nctId":"NCT04374773","phase":"PHASE4","title":"Effects of Pregnancy-associated Hormones on THC Metabolism in Women","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Washington","startDate":"2020-10-19","conditions":"Pregnancy Related, Cannabis Use","enrollment":12},{"nctId":"NCT05491122","phase":"NA","title":"The Influence of Fluid Intake on Daily Biological Rhythm and Mental Performance in Healthy Young Adults","status":"COMPLETED","sponsor":"Liverpool John Moores University","startDate":"2022-11-24","conditions":"Healthy, Habitual; Drinking, Stress, Physiological","enrollment":71},{"nctId":"NCT05816226","phase":"PHASE3","title":"Topical Treatment for TMJ Arthralgia","status":"RECRUITING","sponsor":"University of the Pacific","startDate":"2023-06-01","conditions":"TMJ Pain","enrollment":90},{"nctId":"NCT03736434","phase":"NA","title":"Brain Connections and Blood Pressure","status":"COMPLETED","sponsor":"Ohio State University","startDate":"2018-08-23","conditions":"Hypertension, Mild Cognitive Impairment","enrollment":38},{"nctId":"NCT01186328","phase":"PHASE1","title":"EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL)","status":"TERMINATED","sponsor":"Therapeutic Advances in Childhood Leukemia Consortium","startDate":"2010-08-24","conditions":"Lymphoblastic Leukemia, Acute, Lymphoblastic Leukemia, Acute, Childhood, Leukemia, Lymphoblastic, Acute, T Cell","enrollment":6},{"nctId":"NCT02425852","phase":"PHASE4","title":"A Randomized, Multicenter Open Label Study Comparing Early Administration of Azathioprine Plus IFX to Steroids Plus Azathioprine for Acute Severe Colitis","status":"COMPLETED","sponsor":"Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives","startDate":"2016-12","conditions":"Ulcerative Colitis","enrollment":65},{"nctId":"NCT05688735","phase":"NA","title":"Assessment of the Effect of Coconut and Sunflower Seed Oil Derived Isosorbide Diseters and Colloidial Oatmeal","status":"UNKNOWN","sponsor":"Integrative Skin Science and Research","startDate":"2023-04-20","conditions":"Atopic Dermatitis","enrollment":40},{"nctId":"NCT04137302","phase":"PHASE4","title":"Administration of Hydrocortisone in Young Healthy Male Volunteers","status":"COMPLETED","sponsor":"Centre Hospitalier Régional d'Orléans","startDate":"2019-11-13","conditions":"Anti-doping Campaign, Detection of Hydrocortisone","enrollment":21},{"nctId":"NCT02465606","phase":"PHASE2","title":"A Study to Evaluate the Safety of Lebrikizumab Compared to Topical Corticosteroids in Adult Patients With Atopic Dermatitis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2015-07-30","conditions":"Atopic Dermatitis","enrollment":55},{"nctId":"NCT00823147","phase":"PHASE1","title":"Pain Catastrophizing as a Cause for Systemic Inflammation","status":"COMPLETED","sponsor":"Beth Darnall, PhD","startDate":"2009-01","conditions":"Musculoskeletal Pain","enrollment":93},{"nctId":"NCT02125006","phase":"NA","title":"The Effect of an Inter-Disciplinary Program, Including MBSR, in Breast Cancer Survivors With Chronic Neuropathic Pain","status":"COMPLETED","sponsor":"Ottawa Hospital Research Institute","startDate":"2013-10","conditions":"Breast Cancer, Painful Neuropathy, Chronic Pain","enrollment":118},{"nctId":"NCT03074123","phase":"NA","title":"Cortisol Response to Low Dose Cosyntropin Stimulation Test in the Late Afternoon","status":"COMPLETED","sponsor":"Bnai Zion Medical Center","startDate":"2017-04-01","conditions":"Adrenal Insufficiency","enrollment":20},{"nctId":"NCT02127762","phase":"NA","title":"The Effect of Mindfulness Based Stress Reduction in Patients With Painful Diabetic Peripheral Neuropathy","status":"COMPLETED","sponsor":"Ottawa Hospital Research Institute","startDate":"2012-09","conditions":"Diabetes Mellitus, Type I Diabetes, Type II Diabetes","enrollment":81},{"nctId":"NCT01265017","phase":"PHASE1","title":"Role of Pregnancy Related Hormones in Lowering the Insulin Requirement in Pregnant Women With Type 1 Diabetes","status":"WITHDRAWN","sponsor":"Sansum Diabetes Research Institute","startDate":"2012-07","conditions":"Type 1 Diabetes","enrollment":""},{"nctId":"NCT02419755","phase":"PHASE2","title":"Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies","status":"TERMINATED","sponsor":"St. Jude Children's Research Hospital","startDate":"2015-04-14","conditions":"Mixed Lineage Acute Leukemia, Acute Myeloid Leukemia, Acute Lymphoid Leukemia","enrollment":12},{"nctId":"NCT02340234","phase":"PHASE2","title":"A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2015-05","conditions":"Atopic Dermatitis","enrollment":212},{"nctId":"NCT01313221","phase":"PHASE3","title":"Efficacy and Safety of Etanercept 50 mg Once Weekly Plus As Needed Topical Agent in Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Amgen","startDate":"2011-04","conditions":"Psoriasis","enrollment":310},{"nctId":"NCT02502227","phase":"NA","title":"Mechanisms of Mindfulness Training and Stress Reduction","status":"COMPLETED","sponsor":"Carnegie Mellon University","startDate":"2015-07","conditions":"Psychological Stress, Mindfulness","enrollment":137},{"nctId":"NCT01675232","phase":"NA","title":"A Study Comparing the Efficacy of Two Topical Steroid Application Regimens in Pediatric Patients With Atopic Dermatitis","status":"COMPLETED","sponsor":"Yale University","startDate":"2012-07","conditions":"Atopic Dermatitis","enrollment":45},{"nctId":"NCT02140307","phase":"NA","title":"Relaxation-Response-based Mental Health Promotion - Open and Calm 2013","status":"UNKNOWN","sponsor":"Steen G Hasselbalch","startDate":"2013-01","conditions":"Stress Psychological, Stress Physiological, Quality of Life","enrollment":72}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":24,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Hydrocortisone 2.5%","genericName":"Hydrocortisone 2.5%","companyName":"University of the Pacific","companyId":"university-of-the-pacific","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Hydrocortisone is a glucocorticoid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production. Used for Inflammatory and pruritic dermatological conditions (topical), Eczema, dermatitis, and other inflammatory skin disorders.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}